8-(2,2,2-trifluoroethyl)-1,4-dioxa-8-azaspiro[4.5]-decane | 710350-66-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂螺癸烷衍生物
• 英文名称: 8-(2,2,2-trifluoroethyl)-1,4-dioxa-8-azaspiro[4.5]-decane
• 英文别名: 8-(2,2,2-Trifluoroethyl)-1,4-dioxa-8-azaspiro[4.5]decane
• CAS: 710350-66-6
• 化学式: C₉H₁₄F₃NO₂
• mdl: MFCD23715977
• 分子量: 225.211
• InChiKey: HNIHCKHQRCLHDZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  21.7
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  8-(2,2,2-trifluoroethyl)-1,4-dioxa-8-azaspiro[4.5]-decane 在 盐酸 作用下， 以 水 、 丙酮 为溶剂， 反应 12.0h， 生成 1-(2,2,2-trifluoroethyl)piperidin-4-one hydrochloride
  参考文献：
  名称：

  [EN] HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS
  [FR] COMPOSES CONTENANT UN HALOALKYLE UTILISE COMME INHIBITEURS DE CYSTEINE PROTEASE

  摘要：

  公开号：

  WO2005028429A3
• 作为产物：
  描述：

  2,2,2-trifluoro-1-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)ethan-1-one 在 甲醇 、 四氢呋喃 、 乙酸乙酯 、 Brine 、 magnesium sulfate 作用下， 以 四氢呋喃 、 dimethyl sulfide borane 为溶剂， 反应 12.0h， 以to give 8-(2,2,2-trifluoroethyl)-1,4-dioxa-8-aza-spiro[4.5]decane (19 g)的产率得到8-(2,2,2-trifluoroethyl)-1,4-dioxa-8-azaspiro[4.5]-decane
  参考文献：
  名称：

  Haloalkyl containing compounds as cysteine protease inhibitors

  摘要：

  本发明涉及一种抑制半胱氨酸蛋白酶的化合物，特别是对于B、K、L、F和S型蛋白酶的卡特普辛，因此可用于治疗由这些蛋白酶介导的疾病。本发明涉及包含这些化合物的制药组合物和其制备方法。

  公开号：

  US07547701B2

文献信息

• 1,5,7-TRISUBSTITUTED ISOQUINOLINE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF IN MEDICINES
  申请人：SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD.

  公开号：US20200262813A1

  公开（公告）日：2020-08-20

  The present disclosure relates to 1,5,7-trisubstituted isoquinoline derivatives, their preparation and pharmaceutical use. In particular, the present disclosure discloses a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, and a preparation method and use thereof. The definitions of the groups in the formula can be found in the specification and claims.

  本公开涉及1,5,7-三取代异喹啉衍生物、其制备方法和药物用途。特别是，本公开披露了公式(I)的化合物或其药用可接受的盐、立体异构体、溶剂化物或前药，以及其制备方法和用途。公式的组的定义可以在说明书和权利要求中找到。
• Nicotinamide Derivatives
  申请人：Blake Tanisha D.

  公开号：US20080146569A1

  公开（公告）日：2008-06-19

  The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein the substituents are as defined herein, compositions containing such compounds and the uses of such compounds for the treatment of various diseases and conditions such as asthma.

  本发明涉及公式（I）的化合物及其药用可接受的盐和溶剂化合物，其中取代基如本文所定义，包含这种化合物的组合物以及这种化合物用于治疗各种疾病和状况，如哮喘。
• MNK INHIBITORS AND METHODS RELATED THERETO
  申请人：eFFECTOR Therapeutics, Inc.

  公开号：US20160317536A1

  公开（公告）日：2016-11-03

  The present invention relates to compounds according to Formula (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 4a , R 4b , R 5 , R 6 , R 7 , R 8 , W 1 , W 2 , Y and n are as defined herein. Also described are pharmaceutically acceptable compositions of Formula I compounds as well as methods for utilizing the compounds of Formula I and the pharmaceutically acceptable compositions of Formula I compounds as inhibitors of Mnk as well as therapeutics for the treatment of diseases such as cancer.

  本发明涉及按照式（I）表示的化合物：或其立体异构体、互变异构体或药学上可接受的盐，其中R1、R2、R3、R4a、R4b、R5、R6、R7、R8、W1、W2、Y和n如本文所定义。还描述了按照式（I）化合物的药学上可接受的组合物，以及利用式（I）化合物和药学上可接受的式（I）化合物组合物作为Mnk抑制剂以及治疗癌症等疾病的治疗剂的方法。
• Cyanomethyl derivatives as cysteine protease inhibitors
  申请人：Graupe Michael

  公开号：US20060122184A1

  公开（公告）日：2006-06-08

  The present invention is directed to cyanomethyl derivatives that are inhibitors of cysteine protease, in particular, cathepsin B, K, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.

  本发明涉及氰甲基衍生物，其是半胱氨酸蛋白酶的抑制剂，特别是对于B、K、F和S型的卡特普辛，因此可用于治疗由这些蛋白酶介导的疾病。本发明还涉及包含这些化合物的制药组合物和其制备过程。
• Haloalkyl containing compounds as cysteine protease inhibitors
  申请人：Link O. John

  公开号：US20050182096A1

  公开（公告）日：2005-08-18

  The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.

  本发明涉及抑制半胱氨酸蛋白酶的化合物，特别是cathepsins B、K、L、F和S，因此可用于治疗由这些蛋白酶介导的疾病。本发明涉及包含这些化合物的药物组合物和制备它们的过程。